PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

| C mplet if Kn wn       |                        |  |  |  |  |  |
|------------------------|------------------------|--|--|--|--|--|
| Application Number     | 09/711,709             |  |  |  |  |  |
| Filing Date            | November 13, 2000      |  |  |  |  |  |
| First Named Inventor   | Moshe Kushnir et al.   |  |  |  |  |  |
| Group Art Unit         | 1616                   |  |  |  |  |  |
| Examiner Name          | M.A. Williamson        |  |  |  |  |  |
| Attorney Docket Number | 287985/009 (LR/MCD/YL) |  |  |  |  |  |

|                      |                          |           |                                      | U.S. PATENT DOCU                                | JMENTS   |  |
|----------------------|--------------------------|-----------|--------------------------------------|---|--|--|
| Examiner<br>nitials* | Cite<br>No. <sup>1</sup> | Number    | ment<br>I Code <sup>2</sup><br>nown) | Name of Patentee or Applicant of Cited Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
| MAN                  |                          | 5,474,783 |                                      | Miranda et al.                                  | 12/12/95   |  |
| i l                  |                          | 5,354,885 |                                      | Milman et al.                                   | 10/11/94   |  |
| $\Box$               |                          | 6,166,081 |                                      | Kushnir et al.                                  | 12/26/2000   |  |
| $I \square$          |                          | 5,525,631 |                                      | Milman et al.                                   | 06/11/96   | _  |
|                      |                          | 5,607,969 |                                      | Milman et al.                                   | 03/04/97   | <b>A</b>   |
| MAN                  |                          | 4,035,507 |                                      | Bodor, et al.                                   | 7/12/77  |  |
| ***                  |                          |           |                                      |   | , in   |  |
|                      |                          |           |                                      |   | 1  | 2 0,   |
|                      |                          |           |                                      |   |  | Care   |
|                      |                          |           |                                      |   |  | W2 0.  |
|                      |                          |           | П                                    |   |  | 100 Op 1   |
|                      |                          |           |                                      |   |  | 180 0  |
|                      |                          |           |                                      |   |  | 0/2  |
|                      |                          |           |                                      |   |  | Son.   |
|                      |                          |           |                                      |   |  |  |
|                      |                          |           |                                      | <del>.</del> .                                  |  |  |
|                      |                          |           |                                      |   |  |  |
| $\neg \neg$          | T                        |           |                                      |   |  |  |
|                      |                          |           |                                      |   |  |  |
| $\overline{}$        | <del></del>              |           |                                      |   |  |  |

|                       |              |     |               | FOR  | EIGN PATENT DOCUMENT                               | rs   |  |                |
|-----------------------|--------------|-----|---------------|--|--|--|--|----------------|
| Examiner<br>Initials* | Cite<br>No.1 |     |               | nent<br>Kind Code <sup>5</sup><br>(if known) | Name of Patentee or<br>Applicant of Cited Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
| M                     |              |     | WO 98/16208   |  | Analyst Research Labs.                             | 23 April 1998  |  |                |
|                       |              |     | WO 99/30702   |  | Sekisui Chemical Co.                               | 16 Dec. 1998   |  |                |
|                       |              |     | WO 2000027801 |  | Lidor et al.                                       | 18-05-2000   |  | 1              |
| MA                    |              |     | CA 2112160    |  | Milman et al.                                      | 1993   |  | $\perp$        |
|                       |              |     |               |  | 10.000   |  |  | <u> </u>       |
|                       |              |     |               |  |  |  |  | +              |
|                       |              |     |               |  |  |  |  | $oxed{\bot}$   |
|                       |              | 1 1 |               |  |  | 1  |  | 1              |

| Cignitians Voluments | Signature | Date Considered 9/02 |  |
|----------------------|-----------|----------------------|--|
|----------------------|-----------|----------------------|--|

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| Please | type a                                  | plus si | an (+)   | inside | this | box → | lт |
|--------|---|---------|----------|--------|------|-------|----|
|        | .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | P       | 3··· ( ) |        |      |       |    |

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitut              | ite for form 1449B/PTO | ,    |                 | Compl t if Known       |                        |  |  |
|------------------------|------------------------|------|-----------------|------------------------|------------------------|--|--|
| -                      |                        |      |                 | Application Number     | 09/711,709             |  |  |
| INFC                   | DRMATION               | 1 D  | ISCLOSURE       | Filing Date            | November 13, 2000      |  |  |
| STATEMENT BY APPLICANT |                        |      |                 | First Named Inventor   | Moshe Kushnir et al.   |  |  |
| , –                    |                        |      |                 | Group Art Unit         | 1616                   |  |  |
|                        | (use as many s         | heet | s as necessary) | Examiner Name          | M.A. Williamson        |  |  |
| Sheet                  | 2                      | of   | 2               | Attorney Docket Number | 287985/009 (LR/MCD/YL) |  |  |

|                       |              | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS   |        |  |  |  |  |  |  |
|-----------------------|--------------|---|--------|--|--|--|--|--|--|
| Examiner<br>Initials* | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | 12     |  |  |  |  |  |  |
| Mai                   |              | International Search Report dated 10 February 1998.   | S      |  |  |  |  |  |  |
|                       |              | International Search Report dated 10 February 1998.  Cooper DR, et al. L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J. Pharm. Pharmacol. 1987, 39:627-635.  | all of |  |  |  |  |  |  |
|                       |              | Fix JA, et al. Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption." Pharmaceutical Research. 6 (6):501-505 (1989).  | 20     |  |  |  |  |  |  |
|                       |              | Fix JA, et al. A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice. Pharmaceutical Research. 7(4):384-387 (1990).  | ·      |  |  |  |  |  |  |
|                       |              | Marrel C, et al. L-DOPA esters as Potential prodrugs. Part. II. Chemical and enzymatic hydrolysis. Eur. J. Med. Chem Chem. Ther., 1985-20 No. 5, pp. 467-470.   |        |  |  |  |  |  |  |
|                       |              | Stocchi F, et al. Intravenious Boluses and Continuous Infusions of L-Dopa Methyl Ester in Fluctuating Patients with Parkinson's disease. Move.Disorders, V. 7, No. 3, 1992, pp. 249-256.  |        |  |  |  |  |  |  |
|                       |              | Chemical Abst., CAS Reg. No. 59-92-7 (2000 ACS)   |        |  |  |  |  |  |  |
|                       |              | Chemical Abst., CAS Reg. No. 37178-37-3 (2000 ACS)  |        |  |  |  |  |  |  |
|                       |              | Djaldetti R. et al. Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease. Ann. Neurol. (1996), 39(3), 400-4.  |        |  |  |  |  |  |  |
| MAW                   |              | Ahmed, Ghulam, et al. Facile synthesis of L-Dopa esters by combined use of tyrosinase and .alphachymotrypsin. Biotechnol. Lett. (1994), 16(4), 367-72.  |        |  |  |  |  |  |  |
|                       |              |   |        |  |  |  |  |  |  |
|                       |              |   |        |  |  |  |  |  |  |

| Signature   VV | Examiner  | Mollina   | Date       | 9/    | 67/ |  |
|----------------|-----------|-----------|------------|-------|-----|--|
|                | Signature | Williamso | Considered | 1// ( |     |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

